Mycobacterium avium complex: New drug, Arikayce, receives FDA approval
by Press Release from Outbreak News Today on (#3ZS4F)
The U.S. Food and Drug Administration today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease). MAC is a type of ["]
The post Mycobacterium avium complex: New drug, Arikayce, receives FDA approval appeared first on Outbreak News Today.